OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Roychowdhury on FGFR Mutations in Intrahepatic Cholangiocarcinoma

September 7th 2022

Sameek Roychowdhury, MD, PhD, discusses the prevalence of FGFR mutations in intrahepatic cholangiocarcinoma.

Dr. Litton on Remaining Questions in ESR1-Mutated Breast Cancer

September 7th 2022

Jennifer Keating Litton, MD, discusses research areas of interest in ESR1-mutated, endocrine receptor–positive, HER2-negative breast cancer.

Dr. Kim on the Role of Biomarker Testing in Treatment Decisions for Solid Tumors

September 7th 2022

Edward S. Kim, MD, MBA, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

September 2nd 2022

David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).

Dr. Kaklamani on the Use of Adjuvant Olaparib in Germline BRCA1/2-Mutant Breast Cancer

September 2nd 2022

Virginia G. Kaklamani, MD, discusses the use of adjuvant olaparib in germline BRCA1/2-mutant breast cancer.

Dr. Langer on the Benefit of Atezolizumab Following Progression in Advanced NSCLC

September 1st 2022

Corey J. Langer, MD, discusses the benefit observed with the continued treatment of atezolizumab following disease progression in patients with advanced non–small cell lung cancer.

Dr. Herbst on Considerations for Frontline Immunotherapy in NSCLC

September 1st 2022

Roy S. Herbst, MD, PhD, discusses considerations for frontline immunotherapy in non–small cell lung cancer.

Dr. Winestone on Disparities with Diagnosis in Pediatric Leukemia

August 31st 2022

Lena Winestone, MD, discusses disparities with diagnosis in pediatric leukemia.

Dr. Kim on Clinical Implications of ADCs in HER2+ Solid Tumors

August 31st 2022

Edward S. Kim, MD, MBA, discusses the clinical implications of antibody-drug conjugates in HER2-positive solid tumors.

Dr. Shaukat on the Benefit of Diverse Enrollment in Clinical Trials in CRC

August 31st 2022

Aasma Shaukat, MD, MPH, discusses the benefit of diverse enrollment in clinical trials in colorectal cancer.

Dr. Blay on Treatment Considerations in Soft Tissue Sarcomas

August 31st 2022

Jean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.

Dr. LoRusso on the Benefit of Genetic Sequencing in Sarcomas

August 31st 2022

Patricia LoRusso, DO, discusses the benefit of genetic sequencing in soft tissue sarcomas.

Dr. Martin-Broto on the Current First-Line Treatment of Soft Tissue Sarcomas

August 31st 2022

Javier Martin-Broto, MD, PhD, discusses the current treatment landscape in the first-line setting for soft tissue sarcomas.

Women in Oncology: Prioritization and Passionate Legacies

August 30th 2022

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

Dr. Al-Sawaf on the Benefit of Fixed-Duration Obinutuzumab/Venetoclax in CLL

August 29th 2022

Othman Al-Sawaf, MD, discusses the benefit of fixed-duration treatment with obinutuzumab plus venetoclax in chronic lymphocytic leukemia.

Dr. Barata on the Role of Maintenance Avelumab in Advanced Urothelial Cancer

August 29th 2022

Pedro C. Barata, MD, MSc, discusses the role of maintenance avelumab in advanced urothelial cancer.

Dr. Strickler on the Exploration of Frontline Tucatinib/Trastuzumab in HER2+ CRC

August 29th 2022

John H. Strickler, MD, discusses the investigation of frontline tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Dr. Cohen on the Efficacy of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

August 28th 2022

Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Dr. Raje on the Utilization of bb21217 in Relapsed/ Refractory Multiple Myeloma

August 28th 2022

Noopur Raje, MD, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

Dr. Richardson on Isatuximab Plus Pomalidomide/Dexamethasone in R/R Myeloma

August 27th 2022

Paul G. Richardson, MD, discusses the overall survival benefit displayed by isatuximab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.